Cargando…
A Translational Quantitative Systems Pharmacology Model for CD3 Bispecific Molecules: Application to Quantify T Cell-Mediated Tumor Cell Killing by P-Cadherin LP DART(®)
CD3 bispecific antibody constructs recruit cytolytic T cells to kill tumor cells, offering a potent approach to treat cancer. T cell activation is driven by the formation of a trimolecular complex (trimer) between drugs, T cells, and tumor cells, mimicking an immune synapse. A translational quantita...
Autores principales: | Betts, Alison, Haddish-Berhane, Nahor, Shah, Dhaval K., van der Graaf, Piet H., Barletta, Frank, King, Lindsay, Clark, Tracey, Kamperschroer, Cris, Root, Adam, Hooper, Andrea, Chen, Xiaoying |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6531394/ https://www.ncbi.nlm.nih.gov/pubmed/31119428 http://dx.doi.org/10.1208/s12248-019-0332-z |
Ejemplares similares
-
Molecular imaging reveals biodistribution of P-cadherin LP-DART bispecific and trafficking of adoptively transferred T cells in mouse xenograft model
por: Gupta, Vijay R., et al.
Publicado: (2020) -
A Modeling Framework to Characterize Cytokine Release upon T‐Cell–Engaging Bispecific Antibody Treatment: Methodology and Opportunities
por: Chen, Xiaoying, et al.
Publicado: (2019) -
A Phase 1 Dose-Escalation Study of PF-06671008, a Bispecific T-Cell-Engaging Therapy Targeting P-Cadherin in Patients With Advanced Solid Tumors
por: Harding, James J., et al.
Publicado: (2022) -
The role of multiscale computational approaches for rational design of conventional and nanoparticle oral drug delivery systems
por: Haddish-Berhane, Nahor, et al.
Publicado: (2007) -
Development of PF-06671008, a Highly Potent Anti-P-cadherin/Anti-CD3 Bispecific DART Molecule with Extended Half-Life for the Treatment of Cancer
por: Root, Adam R., et al.
Publicado: (2016)